Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone

Peter Balla, Linda Moskovszky, Z. Sápi, Ramses Forsyth, Helen Knowles, Nick A. Athanasou, M. Szendrői, L. Kópper, Hajnalka Rajnai, Ferenc Pinter, I. Peták, Maria Serena Benassi, Piero Picci, Amalia Conti, T. Krenács

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Aims: Epidermal growth factor receptor (EGFR) is implicated in bone remodelling. The aim was to determine whether EGFR protein expression contributes to the aggressiveness and recurrence potential of giant cell tumour of bone (GCTB), an osteolytic primary bone tumour that can exhibit markedly variable clinical behaviour. Methods and results: Immunohistochemical analysis on tissue microarrays (TMA) of 231 primary, 97 recurrent, 17 metastatic and 26 malignant GCTBs was performed using TMA analysis software and whole digital slides allowing validated scoring. EGFR expression was restricted to neoplastic stromal cells and was significantly more frequent in recurrent (71 of 92; 77%) than in non-recurrent GCTBs (86 of 162; 53%) (P=0.002); and in clinicoradiologically aggressive (31 of 43; 72%) than latent (27 of 54; 50%) cases (P=0.034). Detecting phosphotyrosine epitopes pY1068 and -pY1173 indicated active EGFR signalling, and finding EGFR ligands EGF and transforming growth factor-α restricted to cells of the monocytic lineage suggested paracrine EGFR activation in stromal cells. In functional studies EGF supported proliferation of GCTB stromal cells, and the addition of EGF and macrophage-colony stimulating factor promoted osteoclastogenesis. Conclusion: In GCTB, EGFR signalling in neoplastic stromal cells may contribute to disease progression through promoting stromal cell proliferation and osteoclastogenesis.

Original languageEnglish
Pages (from-to)376-389
Number of pages14
JournalHistopathology
Volume59
Issue number3
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Giant Cell Tumor of Bone
Stromal Cells
Epidermal Growth Factor Receptor
Osteogenesis
Disease Progression
Cell Proliferation
Epidermal Growth Factor
Tissue Array Analysis
Phosphotyrosine
Macrophage Colony-Stimulating Factor
Bone Remodeling
Transforming Growth Factors
Cell Lineage
Epitopes
Software
Ligands
Bone and Bones
Recurrence

Keywords

  • Epidermal growth factor receptor
  • GCTB progression
  • Giant cell tumour of bone
  • Receptor tyrosine kinases

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine

Cite this

Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone. / Balla, Peter; Moskovszky, Linda; Sápi, Z.; Forsyth, Ramses; Knowles, Helen; Athanasou, Nick A.; Szendrői, M.; Kópper, L.; Rajnai, Hajnalka; Pinter, Ferenc; Peták, I.; Benassi, Maria Serena; Picci, Piero; Conti, Amalia; Krenács, T.

In: Histopathology, Vol. 59, No. 3, 09.2011, p. 376-389.

Research output: Contribution to journalArticle

Balla, Peter ; Moskovszky, Linda ; Sápi, Z. ; Forsyth, Ramses ; Knowles, Helen ; Athanasou, Nick A. ; Szendrői, M. ; Kópper, L. ; Rajnai, Hajnalka ; Pinter, Ferenc ; Peták, I. ; Benassi, Maria Serena ; Picci, Piero ; Conti, Amalia ; Krenács, T. / Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone. In: Histopathology. 2011 ; Vol. 59, No. 3. pp. 376-389.
@article{388ab01c21934c9b9c2b5a163f2764ca,
title = "Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone",
abstract = "Aims: Epidermal growth factor receptor (EGFR) is implicated in bone remodelling. The aim was to determine whether EGFR protein expression contributes to the aggressiveness and recurrence potential of giant cell tumour of bone (GCTB), an osteolytic primary bone tumour that can exhibit markedly variable clinical behaviour. Methods and results: Immunohistochemical analysis on tissue microarrays (TMA) of 231 primary, 97 recurrent, 17 metastatic and 26 malignant GCTBs was performed using TMA analysis software and whole digital slides allowing validated scoring. EGFR expression was restricted to neoplastic stromal cells and was significantly more frequent in recurrent (71 of 92; 77{\%}) than in non-recurrent GCTBs (86 of 162; 53{\%}) (P=0.002); and in clinicoradiologically aggressive (31 of 43; 72{\%}) than latent (27 of 54; 50{\%}) cases (P=0.034). Detecting phosphotyrosine epitopes pY1068 and -pY1173 indicated active EGFR signalling, and finding EGFR ligands EGF and transforming growth factor-α restricted to cells of the monocytic lineage suggested paracrine EGFR activation in stromal cells. In functional studies EGF supported proliferation of GCTB stromal cells, and the addition of EGF and macrophage-colony stimulating factor promoted osteoclastogenesis. Conclusion: In GCTB, EGFR signalling in neoplastic stromal cells may contribute to disease progression through promoting stromal cell proliferation and osteoclastogenesis.",
keywords = "Epidermal growth factor receptor, GCTB progression, Giant cell tumour of bone, Receptor tyrosine kinases",
author = "Peter Balla and Linda Moskovszky and Z. S{\'a}pi and Ramses Forsyth and Helen Knowles and Athanasou, {Nick A.} and M. Szendrői and L. K{\'o}pper and Hajnalka Rajnai and Ferenc Pinter and I. Pet{\'a}k and Benassi, {Maria Serena} and Piero Picci and Amalia Conti and T. Kren{\'a}cs",
year = "2011",
month = "9",
doi = "10.1111/j.1365-2559.2011.03948.x",
language = "English",
volume = "59",
pages = "376--389",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone

AU - Balla, Peter

AU - Moskovszky, Linda

AU - Sápi, Z.

AU - Forsyth, Ramses

AU - Knowles, Helen

AU - Athanasou, Nick A.

AU - Szendrői, M.

AU - Kópper, L.

AU - Rajnai, Hajnalka

AU - Pinter, Ferenc

AU - Peták, I.

AU - Benassi, Maria Serena

AU - Picci, Piero

AU - Conti, Amalia

AU - Krenács, T.

PY - 2011/9

Y1 - 2011/9

N2 - Aims: Epidermal growth factor receptor (EGFR) is implicated in bone remodelling. The aim was to determine whether EGFR protein expression contributes to the aggressiveness and recurrence potential of giant cell tumour of bone (GCTB), an osteolytic primary bone tumour that can exhibit markedly variable clinical behaviour. Methods and results: Immunohistochemical analysis on tissue microarrays (TMA) of 231 primary, 97 recurrent, 17 metastatic and 26 malignant GCTBs was performed using TMA analysis software and whole digital slides allowing validated scoring. EGFR expression was restricted to neoplastic stromal cells and was significantly more frequent in recurrent (71 of 92; 77%) than in non-recurrent GCTBs (86 of 162; 53%) (P=0.002); and in clinicoradiologically aggressive (31 of 43; 72%) than latent (27 of 54; 50%) cases (P=0.034). Detecting phosphotyrosine epitopes pY1068 and -pY1173 indicated active EGFR signalling, and finding EGFR ligands EGF and transforming growth factor-α restricted to cells of the monocytic lineage suggested paracrine EGFR activation in stromal cells. In functional studies EGF supported proliferation of GCTB stromal cells, and the addition of EGF and macrophage-colony stimulating factor promoted osteoclastogenesis. Conclusion: In GCTB, EGFR signalling in neoplastic stromal cells may contribute to disease progression through promoting stromal cell proliferation and osteoclastogenesis.

AB - Aims: Epidermal growth factor receptor (EGFR) is implicated in bone remodelling. The aim was to determine whether EGFR protein expression contributes to the aggressiveness and recurrence potential of giant cell tumour of bone (GCTB), an osteolytic primary bone tumour that can exhibit markedly variable clinical behaviour. Methods and results: Immunohistochemical analysis on tissue microarrays (TMA) of 231 primary, 97 recurrent, 17 metastatic and 26 malignant GCTBs was performed using TMA analysis software and whole digital slides allowing validated scoring. EGFR expression was restricted to neoplastic stromal cells and was significantly more frequent in recurrent (71 of 92; 77%) than in non-recurrent GCTBs (86 of 162; 53%) (P=0.002); and in clinicoradiologically aggressive (31 of 43; 72%) than latent (27 of 54; 50%) cases (P=0.034). Detecting phosphotyrosine epitopes pY1068 and -pY1173 indicated active EGFR signalling, and finding EGFR ligands EGF and transforming growth factor-α restricted to cells of the monocytic lineage suggested paracrine EGFR activation in stromal cells. In functional studies EGF supported proliferation of GCTB stromal cells, and the addition of EGF and macrophage-colony stimulating factor promoted osteoclastogenesis. Conclusion: In GCTB, EGFR signalling in neoplastic stromal cells may contribute to disease progression through promoting stromal cell proliferation and osteoclastogenesis.

KW - Epidermal growth factor receptor

KW - GCTB progression

KW - Giant cell tumour of bone

KW - Receptor tyrosine kinases

UR - http://www.scopus.com/inward/record.url?scp=80053322539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053322539&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2559.2011.03948.x

DO - 10.1111/j.1365-2559.2011.03948.x

M3 - Article

C2 - 22034878

AN - SCOPUS:80053322539

VL - 59

SP - 376

EP - 389

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 3

ER -